Pfizer besides Prevnar you got a bad deal for 68 billion

Discussion in 'Wyeth' started by Anonymous, Oct 14, 2009 at 5:34 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    What have you got
    Zosyn generic right now-goodbye a billion a year
    Effexor XR- goodbye 3-4 billion/a year next year
    Enbrel US rights gone 2012/2-3 billion a year
    Your losing Lipitor
    R and D sucks Sutent usage will be limited Liver problems
    Relistor gone back to Progenics they will get oral formulation and
    chronic pain 100-200 million dollars not good enough for greedy Pfizer
    Torisel and Tygacil not new indications or studies dead products maybe 200 million tops
    Pristique HOWEVER YOU SPELL a joke to sell-generic Zoloft better
    Premarin Cream watch the lawsuits coming
    Alzheimers drug phase 3 once looked promising -concerns about side effects probably not a blockbuster
    If you stay its only for a short time every year the same bs deep cuts
    Management has no clue how to deal with changes in the new health care environment which will make sales jobs even harder
    So as Howie says on Deal or no Deal Pfizer you made a BAD BAD deal-Kindler should be kicked out and i bet stock will be half the price end of 2010-Kindler got a extra year or 2
    Peace you Wyeth Friend- over 55 and hopes to be long gone
     

  2. Anonymous

    Anonymous Guest

    screw you wyeth prick well deal with you
     
  3. Anonymous

    Anonymous Guest

    it's hard to disagree with any of these points. Both companies were screwed on their own, together it's one company that's really screwed. They should have bought the company that makes Snuggies instead.
     
  4. Anonymous

    Anonymous Guest

    Should have gone after Abbott or partnered with Novartis or GSK & their deep pipelines.

    Better start hooking up with some device companies like Stryker, Medtronic & get major stake in promotion partner Bausch & Lomb. Novartis is buying major stake in Alcon.

    Devices & biotech don't have the patent cliffs and generic competition like the old pharma business model. This will go down as a marketing blunder on Pfizer's part and grease the skids for Kindler's departure.
     
  5. Anonymous

    Anonymous Guest

    Post number 4 you speak wisdom those are the companies to interview not the old pharma
    model that is dead as a door nail
     
  6. Anonymous

    Anonymous Guest

    Get me out of here now -Sounds like hell
     
  7. Anonymous

    Anonymous Guest

    Hell with a paycheck. If you're let go you get a package. If you're kept, you continue getting a paycheck. Either way you win. The downfall to all of this is, yes, most of us hate this. Pharma has its nose above the water line right now. Pfizer buying our company is like salt in the wound. BUT, keep in mind the paycheck or severance package.
    If you stay and continue with a paycheck through the hell that's yet to come you're a winner....it's still a paycheck. The only next big decisions to look forward to is not getting fired before the next round of layoffs that will offer a severance package.

    Get it??
     
  8. Anonymous

    Anonymous Guest

    Study shows no drop in rate of childhood pneumonia after vaccine
    A study on the rates of childhood pneumonia shows no difference in the number of cases after the vaccine became available. Pfizer's (PFE) vaccine "Prevnar" cited.

    According to Reuters, in "the first study to provide national estimates of childhood pneumonia, they found rates of the lung infection had stayed more or less constant between 1994 and 2007.

    At the beginning of that period, 19 in 1,000 children got a pneumonia diagnosis at the doctor's office or at an emergency department, compared to 22 in 1,000 at the end.

    But that doesn't mean the vaccine -- Pfizer's Prevnar, or PCV7 -- has been useless.

    For instance, earlier work found the number of kids who had to be treated for pneumonia at the hospital dropped by more than half after the vaccine became available.

    "It's possible that the vaccination has had a major impact on the more serious complications of pneumonia," said Dr. Samir S. Shah of the University of Pennsylvania School of Medicine in Philadelphia, who led the work.

    Prevnar protects against a type of bacteria called Streptococcus pneumoniae, or just pneumococcus, which causes several kinds of infections -- including pneumonia, meningitis and middle ear infections.

    "If you look at how effective the vaccine was in reducing meningitis and blood infections, it has done a phenomenal job," said Shah, whose study was supported by the National Institutes of Health.

    While Pfizer said Prevnar is not licensed to prevent pneumonia in the U.S., it stressed the new study's design might be shrouding possible effects of the vaccine on the disease."


    http://flucrazy.blogspot.com/2011/02/study-shows-no-drop-in-rate-of.html
     
  9. Anonymous

    Anonymous Guest

    Completely agree...WHAT Rx products did they REALLY acquire?!

    Comically, Pfizer had divested all of their OTC meds. With the Wyeth acquisition, they reentered that market. So, Pfizer IS generating the OTC dollars...which are not as profitable as the Rx products.

    Completely agree as well...the old Rx model is dead. Get out while you can! Good luck tho, as many companies don't view Rx sales as SALES...yet promotion.

    Take care~